Logo image of ATAI

ATAI LIFE SCIENCES NV (ATAI) Stock Fundamental Analysis

NASDAQ:ATAI - NL0015000DX5 - Common Stock

4.57 USD
-0.26 (-5.38%)
Last: 8/27/2025, 8:00:01 PM
4.65 USD
+0.08 (+1.75%)
After Hours: 8/27/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ATAI. ATAI was compared to 193 industry peers in the Pharmaceuticals industry. ATAI has a great financial health rating, but its profitability evaluates not so good. ATAI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATAI had negative earnings in the past year.
ATAI had a negative operating cash flow in the past year.
In the past 5 years ATAI always reported negative net income.
ATAI had a negative operating cash flow in each of the past 5 years.
ATAI Yearly Net Income VS EBIT VS OCF VS FCFATAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

ATAI's Return On Assets of -78.89% is on the low side compared to the rest of the industry. ATAI is outperformed by 70.98% of its industry peers.
ATAI has a Return On Equity of -103.85%. This is comparable to the rest of the industry: ATAI outperforms 41.45% of its industry peers.
Industry RankSector Rank
ROA -78.89%
ROE -103.85%
ROIC N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ATAI Yearly ROA, ROE, ROICATAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ATAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATAI Yearly Profit, Operating, Gross MarginsATAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

7

2. Health

2.1 Basic Checks

ATAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ATAI has been increased compared to 1 year ago.
The number of shares outstanding for ATAI has been increased compared to 5 years ago.
ATAI has a worse debt/assets ratio than last year.
ATAI Yearly Shares OutstandingATAI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
ATAI Yearly Total Debt VS Total AssetsATAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 6.83 indicates that ATAI is not in any danger for bankruptcy at the moment.
ATAI's Altman-Z score of 6.83 is amongst the best of the industry. ATAI outperforms 82.38% of its industry peers.
There is no outstanding debt for ATAI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.83
ROIC/WACCN/A
WACC7.29%
ATAI Yearly LT Debt VS Equity VS FCFATAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.02 indicates that ATAI has no problem at all paying its short term obligations.
ATAI has a better Current ratio (4.02) than 65.80% of its industry peers.
A Quick Ratio of 4.02 indicates that ATAI has no problem at all paying its short term obligations.
ATAI has a better Quick ratio (4.02) than 66.84% of its industry peers.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 4.02
ATAI Yearly Current Assets VS Current LiabilitesATAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

ATAI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -72.50%.
The Revenue has decreased by -1.91% in the past year.
Measured over the past years, ATAI shows a very negative growth in Revenue. The Revenue has been decreasing by -75.28% on average per year.
EPS 1Y (TTM)-72.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.11%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%163.37%

3.2 Future

ATAI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.45% yearly.
Based on estimates for the next years, ATAI will show a very strong growth in Revenue. The Revenue will grow by 238.35% on average per year.
EPS Next Y48.51%
EPS Next 2Y23.19%
EPS Next 3Y13.79%
EPS Next 5Y13.45%
Revenue Next Year314.74%
Revenue Next 2Y-41.84%
Revenue Next 3Y332.61%
Revenue Next 5Y238.35%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATAI Yearly Revenue VS EstimatesATAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ATAI Yearly EPS VS EstimatesATAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATAI. In the last year negative earnings were reported.
Also next year ATAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATAI Price Earnings VS Forward Price EarningsATAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATAI Per share dataATAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as ATAI's earnings are expected to grow with 13.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.19%
EPS Next 3Y13.79%

More info and screens

0

5. Dividend

5.1 Amount

ATAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATAI LIFE SCIENCES NV

NASDAQ:ATAI (8/27/2025, 8:00:01 PM)

After market: 4.65 +0.08 (+1.75%)

4.57

-0.26 (-5.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners9.44%
Inst Owner Change-0.75%
Ins Owners2.69%
Ins Owner Change28.14%
Market Cap979.53M
Analysts84
Price Target11.51 (151.86%)
Short Float %8.21%
Short Ratio2.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.25%
Min EPS beat(2)-17.64%
Max EPS beat(2)17.15%
EPS beat(4)1
Avg EPS beat(4)-15.72%
Min EPS beat(4)-62.27%
Max EPS beat(4)17.15%
EPS beat(8)4
Avg EPS beat(8)10%
EPS beat(12)7
Avg EPS beat(12)5.89%
EPS beat(16)9
Avg EPS beat(16)-5.32%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.77%
PT rev (3m)30.22%
EPS NQ rev (1m)6.36%
EPS NQ rev (3m)35.63%
EPS NY rev (1m)1.17%
EPS NY rev (3m)30.45%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)45.56%
Revenue NY rev (3m)122.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3180.3
P/FCF N/A
P/OCF N/A
P/B 6.81
P/tB 6.98
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS0.67
TBVpS0.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.89%
ROE -103.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 830.23%
Cap/Sales 2024.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 4.02
Altman-Z 6.83
F-Score2
WACC7.29%
ROIC/WACCN/A
Cap/Depr(3y)268.35%
Cap/Depr(5y)673.01%
Cap/Sales(3y)220.74%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.11%
EPS Next Y48.51%
EPS Next 2Y23.19%
EPS Next 3Y13.79%
EPS Next 5Y13.45%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%163.37%
Revenue Next Year314.74%
Revenue Next 2Y-41.84%
Revenue Next 3Y332.61%
Revenue Next 5Y238.35%
EBIT growth 1Y18.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.41%
EBIT Next 3Y-15.65%
EBIT Next 5Y-3.12%
FCF growth 1Y21.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.11%
OCF growth 3YN/A
OCF growth 5YN/A